Combination treatment for advanced HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of drugs (zanidatamab, tucatinib, and chemotherapy) for people with advanced HER2-positive breast cancer that has stopped responding to previous treatments. The goal is to see if this combination can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have HER2-positive breast cancer that has spread locally or to other parts of the body and cannot be removed with surgery.
- Your cancer has grown after at least one previous treatment for advanced disease, but you have had no more than three such treatments.
- You are physically able to care for yourself and are up and about (ECOG score 0 or 1).
- You have adequate organ function (bone marrow, liver, kidneys) and are willing to provide blood and tissue samples.
- If you have brain metastases, they must be stable or not require immediate local treatment.
- If you are of childbearing potential, you must agree to use highly effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches how well a three-drug combination (tucatinib, capecitabine, and trastuzumab) works for women with breast cancer that has spread to other parts of the body and has a protein called HER2. You'll be treated as you normally would be in a clinic, and researchers will track how you respond.
This trial tests a combination of three drugs (chidamide, a PD-1 inhibitor, and anlotinib) to see if they can shrink or slow the growth of advanced breast cancer that is HER2-low and hormone receptor positive, and has stopped responding to endocrine therapy.
This trial tests a new drug called zanidatamab combined with chemotherapy to shrink HER2-positive breast cancer before surgery. It may help improve treatment outcomes for people with stage 2 or 3 breast cancer that has not spread.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
This study tests two drugs together—trastuzumab deruxtecan and ivonescimab—for advanced breast cancer that is hormone-receptor-positive but HER2-negative or HER2-low. These drugs work by targeting cancer cells in different ways and may help slow or shrink tumors in patients whose cancer has progressed after earlier treatments.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.